Vanguard Group’s TriVascular Technologies TRIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
– Sell
-132,503
Closed -$882K – 4189
2015
Q4
$882K Buy
132,503
+4,765
+4% +$31.6K ﹤0.01% 3662
2015
Q3
$639K Buy
127,738
+4,948
+4% +$26.6K ﹤0.01% 3775
2015
Q2
$657K Sell
122,790
-4,445
-3% -$31.5K ﹤0.01% 3786
2015
Q1
$1.34M Buy
127,235
+11,238
+10% +$116K ﹤0.01% 3549
2014
Q4
$1.46M Buy
115,997
+55,439
+92% +$756K ﹤0.01% 3394
2014
Q3
$877K Buy
60,558
+5,496
+10% +$79.8K ﹤0.01% 3551
2014
Q2
$857K Buy
+55,062
New +$836K ﹤0.01% 3523

Vanguard Group's TRIV Position: Q1 2016 in Review

Vanguard Group sold out of TriVascular Technologies (TRIV) in Q1 2016, closing a stake of 132,503 shares — an estimated $882K sold.

Vanguard Group first reported a position in TRIV in Q2 2014 and held it in 7 quarters. The position peaked at $1.46M in Q4 2014. 0 funds tracked by Wall St. Rank hold TRIV as of Q1 2016.

  • Vanguard Group reported no remaining TriVascular Technologies position as of Q1 2016 after selling out during the quarter.
  • Vanguard Group sold 132,503 TriVascular Technologies shares in Q1 2016, an estimated $882K.
  • Vanguard Group first reported a position in TriVascular Technologies in Q2 2014 and held it in 7 quarters.
  • Vanguard Group's TriVascular Technologies position peaked at $1.46M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held TriVascular Technologies as of Q1 2016.

Based on Vanguard Group's 13F filing for Q1 2016, filed 13 May 2016.